Alkermes to unveil data from ARISTADA schizophrenia study

Alkermes PLC will present data for the two-month dosing option of ARISTADA (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia at the 16th International Congress on Schizophrenia Research (ICOSR) in San Diego Friday through Monday.
The event will mark the first time the company unveils data about the investigational two-month dosing option of ARISTADA at a medical meeting. Alkermes will showcase a poster titled “Pharmacokinetic Analysis of a 2-Month Regimen of Aripiprazole Lauroxil” at noon on Saturday in the Grand Hall at the event.
“Schizophrenia is a complex condition in which symptoms and severity of the disease varies, and healthcare providers need a variety of options to help individualize treatment based on patient needs,” Dr. Elliot Ehrich, chief medical officer of Alkermes, said in a statement. “We are designing ARISTADA to offer unprecedented flexibility in terms of doses and dosing intervals, and we believe a two-month offering of ARISTADA could be an important new treatment option for the treatment of schizophrenia.”
 Alkermes noted in its press release that the U.S. Food and Drug Administration is reviewing a supplemental New Drug Application (sNDA) for the two-month dosing option of ARISTADA.